Medication approval journey
alprazolam (Xanax)
Approved for Generalized anxiety disorder and panic disorder
page first published · last updated
Also answers to “the panic snooze button” — its codename in our videos and posts. The full codebook
How this page reads
The page as written, with the clinical terms
Plain language uses the same facts, the same numbers and the same caveats. It does not leave anything out. Quotes from the FDA label are never reworded in either setting.
Before you stop or change your alprazolam dose
Stopping abruptly can be dangerous — never do it without medical supervision
Do not stop a benzodiazepine abruptly. Abrupt withdrawal can cause seizures, delirium, and can be fatal. Physical dependence develops within weeks of daily use and is not the same thing as addiction. Coming off safely is a prescriber-supervised taper measured in months, sometimes far longer, and going slower is not failure.
what the alprazolam warnings mean
label facts below are read from the alprazolam tablets FDA label on DailyMed, set id 563e09db-2f3d-4ce8-b356-ae44477be6d0, version 2, effective august 27, 2026. the section numbers in brackets are the label’s own. every source is linked at the end of this section. last checked 2026-10-05.
alprazolam was approved in october 1981 for anxiety and panic disorder, and about 3.4 million americans filled a prescription for it in 2024, down from about 5.5 million in 2014 [meps]. it is a schedule iv controlled substance. its label opens with a three-part boxed warning that the fda rewrote for every benzodiazepine in september 2020, followed by nine further numbered warnings. this section says what each means in plain words, what the label itself says about tapering, what the approval trials measured and for how long, which side effects the label counts and how often, and what independent research has found since, in both directions. every number is from the label, an fda communication, or a study in the library, and each source is linked at the end.
this is information to take to a prescriber. nothing here is a reason to start, stop or change a dose on your own; with this drug the label says that stopping abruptly can be life-threatening, and the taper schedule quoted below is the label’s, not ours.
the boxed warning, part one: opioids
the first part of the boxed warning says that using benzodiazepines with opioids "may result in profound sedation, respiratory depression, coma, and death", that the two should be prescribed together only when alternatives are inadequate, at the lowest doses for the shortest time, with the patient followed for slowed breathing and sedation [label, boxed warning and 5.1]. the label explains why the two add rather than cancel: they slow breathing through different receptors [xr-label]. if one drug is added to the other, the label says to start the second at a lower dose than usual [label 5.1].
the numbers behind it are observational. among 315,428 insured american adults who filled an opioid prescription between 2001 and 2013, the share also filling a benzodiazepine rose from 9% to 17%, and those taking both had 2.14 times the odds of an emergency visit or admission for opioid overdose [sun-2017]. across 399,230 us opioid overdose deaths from 1999 to 2017, benzodiazepine involvement rose from 8.7% to 21.0%, and benzodiazepines were present in 33.1% of prescription-opioid deaths in 2017 [tori-2020]. in cdc surveillance for the first half of 2018, 62.6% of opioid deaths also involved cocaine, methamphetamine or a benzodiazepine, and counterfeit pills sold as xanax were among the ways fentanyl reached people [gladden-2019]. none of these studies can prove the benzodiazepine caused the deaths; all of them count it there.
the boxed warning, parts two and three: abuse, misuse and addiction; dependence and withdrawal
the second part says benzodiazepines expose users to "risks of abuse, misuse, and addiction, which can lead to overdose or death", that abuse and misuse commonly involve other medicines, alcohol or illicit drugs, and that prescribers should assess each person’s risk before prescribing and throughout treatment [label, boxed warning and 5.2]. the label adds that misuse often, but not always, involves doses above the maximum, and that "even taking benzodiazepines as prescribed may put patients at risk for abuse and misuse" [label 9.2]. death, it says, "is more often associated with polysubstance use", especially with opioids and alcohol [label 9.2].
the third part says that continued use "may lead to clinically significant physical dependence", that the risk rises with longer treatment and higher doses, and that stopping abruptly or cutting the dose quickly "may precipitate acute withdrawal reactions, which can be life-threatening", so the dose should be reduced by a gradual taper [label, boxed warning and 5.3]. the fda required this wording on every benzodiazepine in september 2020; the point of it is that dependence can develop when the drug is taken exactly as prescribed, which is a reason not to stop on one’s own [fda-2020].
the label puts some numbers on dependence. "even after relatively short-term use at doses of < 4 mg/day, there is some risk of dependence." reports suggest the risk and severity are greater above 4 mg a day and beyond 12 weeks; in a controlled discontinuation study, people on more than 4 mg a day had more difficulty tapering to zero, while three months against six months of treatment made no difference [label 5.3]. in a trial of 63 people where withdrawal symptoms were deliberately sought, they included heightened senses, poor concentration, altered smell, clouded thinking, tingling, muscle cramps and twitches, diarrhea, blurred vision and loss of appetite and weight; anxiety and insomnia were common too but could not be told apart from the illness returning [label 5.3]. the label also describes "interdose" symptoms, early-morning anxiety and anxiety between doses in people on steady maintenance, as a sign the dose is wearing off before the next one [label 5.3]. a protracted withdrawal syndrome, with anxiety, cognitive impairment, depression, insomnia, tinnitus and motor symptoms, can last "weeks to more than 12 months" [label 5.3, 9.3].
what the label says about tapering
the label’s instruction, quoted so that it is the label’s and not ours: "reduce the dosage by no more than 0.5 mg every 3 days. some patients may benefit from an even more gradual discontinuation. some patients may prove resistant to all discontinuation regimens." if withdrawal reactions appear, it says to pause the taper or return to the previous step and then go more slowly [label 2.3]. in a controlled post-marketing study comparing that schedule with a slower one, the same proportion reached zero either way, but the slower schedule produced fewer withdrawal symptoms [label 2.3].
on panic disorder it is candid: the necessary duration of treatment "is unknown", a supervised taper may be attempted after an extended period free of panic attacks, "but there is evidence that this may often be difficult to accomplish without recurrence of symptoms and/or the manifestation of withdrawal phenomena" [label 2.2]. people on more than 4 mg a day for three months were able to taper to half their dose without apparent loss of benefit [label 2.2]. the uk guideline for these medicines says the same in different words: do not stop abruptly, taper in steps proportionate to the current dose so the steps shrink as the dose falls, and expect that withdrawal "may take several months or more" [nice-2022]. a cochrane review of 38 trials in 2,543 long-term benzodiazepine users found no add-on medication that reliably improved the chance of stopping, leaving the gradual taper as the mainstay [baandrup-2018].
the other warnings, in plain words
the warnings section runs from 5.1 to 5.9; the first three are the boxed warning spelled out. the rest:
- driving and alcohol [5.4]: a cns depressant; the label says to avoid hazardous activities until the effect is known and to avoid alcohol and other sedatives.
- drugs that block its breakdown [5.5]: alprazolam is cleared by the liver enzyme cyp3a. ketoconazole raised its blood level 3.98-fold and itraconazole 2.70-fold, so strong cyp3a inhibitors such as the azole antifungals are contraindicated, except ritonavir, with which the dose is halved for the first 10 to 14 days [label 4, 2.6]. nefazodone, fluvoxamine and cimetidine also raise levels. the opposite happens with st john’s wort, which in healthy volunteers halved alprazolam exposure and shortened its half-life from 12.4 to 6.0 hours after two weeks [markowitz-2003].
- depression [5.6]: benzodiazepines may worsen depression; panic disorder travels with depression and with suicide among untreated people, so the label says to limit the quantity dispensed and watch for suicidal thinking.
- mania [5.7]: episodes of hypomania and mania have been reported in people with depression taking alprazolam.
- pregnancy [5.8]: use late in pregnancy can leave a newborn sedated (slow breathing, floppiness) or in withdrawal (irritability, tremor, inconsolable crying, feeding problems); this subsection was added in january 2023 [label 5.8, recent major changes].
- breathing [5.9]: deaths have been reported in people with severe lung disease shortly after starting; the label says to monitor anyone with impaired breathing and stop the drug if breathing slows.
what the approval trials measured, and for how long
the anxiety indication rests on 4-week placebo-controlled trials at up to 4 mg a day. the label does not say how many trials there were or how many people were in them; the only sizes it gives are from the side-effect tables, 565 on alprazolam and 505 on placebo. it reports that alprazolam beat placebo at every assessment on five rating scales [label 14.1]. the approval is for the "acute treatment" of generalized anxiety disorder, and the trials are four weeks long [label 1].
the panic indication rests on three placebo-controlled trials of up to 10 weeks. the average dose was 5 to 6 mg a day in two of them, and the third fixed doses at 2 and 6 mg. in all three, more people on alprazolam had zero panic attacks (37% to 83% met that criterion), and in two of three the weekly count of attacks fell by more [label 14.2]. the largest, an 8-week trial in 526 people, found 50% panic-free at week 4 against 28% on placebo, with benefit in the first week [ballenger-1988]. a subgroup who improved was followed openly for up to 8 months "without apparent loss of benefit", which is the longest the label has [label 14.2]. nothing in the label is placebo-controlled beyond ten weeks.
side effects, with the label’s numbers
the two indications have very different numbers because the doses differ. in the 4-week anxiety trials at up to 4 mg (565 against 505 on placebo): drowsiness 41% against 22%, light-headedness 21% against 19%, dry mouth 15% against 13%, low blood pressure 5% against 2% [label 6.1, table 1].
in the panic trials at up to 10 mg (1,388 against 1,231 on placebo): drowsiness 77% against 43%, fatigue 49% against 42%, impaired coordination 40% against 18%, memory impairment 33% against 22%, irritability 33% against 30%, cognitive disorder 29% against 21%, slurred speech 23% against 6%, constipation 26% against 15%, increased appetite 33% against 23%, weight gain 27% against 18%, decreased libido 14% against 8%, increased libido 8% against 4%, sexual dysfunction 7% against 4% [label 6.1, table 2]. the label adds that little tolerance develops to the memory and cognitive effects even as tolerance to the calming effect may grow [label 9.3].
the label also counts what happened when 641 people in the panic programme came off the drug: insomnia 29.5%, light-headedness 19.3%, anxiety 19.2%, fatigue 18.4%, abnormal involuntary movements 17.3%, headache 17.0%, nausea or vomiting 16.5%, sweating 14.4%, diarrhea 13.6%, weight loss 13.3%, fast heartbeat 12.2%, blurred vision 10.0% [label 6.1, table 3]. withdrawal seizures have followed rapid reduction or abrupt stopping. paradoxical reactions, agitation, rage, hallucinations and aggression, are rare and the label says to stop the drug if they occur [label 6.1].
what the research says, in both directions
in favour. a 2023 cochrane network meta-analysis of 70 trials, up to 12,310 people, found alprazolam among the most effective and best-tolerated drugs for panic disorder, and one of only two that clearly reduced the frequency of panic attacks against placebo [guaiana-2023]. the 526-person trial above found half of people panic-free at four weeks against 28% [ballenger-1988]. a prospective cohort of 3,434 adults aged 65 and over, followed for a mean of 7.3 years, found no increased dementia risk in the heaviest benzodiazepine users (hazard ratio 1.07, 95% ci 0.82 to 1.39), and no dose-response, which argues against a causal link [gray-2016].
against, or smaller than it sounds. the same cochrane review judged the trial quality low enough to limit confidence [guaiana-2023], and a meta-analysis of 8 trials in 631 people found alprazolam no more effective than other benzodiazepines on panic frequency, anxiety scores or the share who became panic-free [moylan-2011]; its distinguishing feature is a shorter action, which is also what produces interdose symptoms [label 5.3]. a case-control study of 1,796 older adults with alzheimer’s disease and 7,184 controls found past benzodiazepine use beyond three months associated with about 1.5 times the odds of alzheimer’s, rising to 1.8 with longer cumulative use; anxiety and insomnia can be early symptoms of dementia, so the direction of cause is unsettled, and the prospective cohort above points the other way [billioti-2014]. a meta-analysis of 13 observational studies of people who had taken benzodiazepines for about 10 years found them scoring moderately worse than controls across every cognitive domain tested (effect size 0.74) [barker-2004]. the 1988 trial drew contemporary critiques about how durable the advantage was beyond the first weeks and about rebound and dependence on stopping [ballenger-1988].
the warnings, measured. the opioid warning’s size is in the three studies above: twice the odds of an overdose visit with concurrent prescriptions [sun-2017], one in three prescription-opioid deaths with a benzodiazepine present [tori-2020], and two thirds of opioid deaths involving another drug [gladden-2019]. the dependence warning’s timescale is in the uk guideline [nice-2022] and in the cochrane finding that no medicine makes stopping reliably easier [baandrup-2018].
questions to ask your prescriber about alprazolam
each one comes from a warning or a study above. they are questions, not instructions; the answers depend on a history nobody here has.
- the label says dependence can develop even at under 4 mg a day taken as prescribed. how long is the plan for me to be on this, and when will we review it?
- if we ever reduce or stop, the label says no more than 0.5 mg every 3 days and slower if needed. what would my schedule look like, and how would we tell withdrawal from my anxiety coming back?
- is any opioid in my life, prescribed or not, including a cough medicine or a pain pill after surgery? the boxed warning is about the combination, and both prescribers need to know.
- i take an antifungal, an antibiotic, an hiv medicine, fluvoxamine or st john’s wort. the label lists drugs that raise or lower alprazolam levels; is anything i take on that list?
- in the panic trials, drowsiness was 77% and impaired coordination 40%. what should i not do until we know how it affects me, and does my job or my driving change that?
- i get anxious before the next dose is due. the label calls this an interdose symptom. is it the dose wearing off, and what does that mean for how we use it?
- is naloxone in the house, and do the people around me know how to use it, given what is also prescribed here?
questions people ask
- what does the xanax (alprazolam) black box warning mean?
- it has three parts, rewritten by the fda for every benzodiazepine in september 2020. first, taking a benzodiazepine with an opioid can cause profound sedation, slowed breathing, coma and death, so the two should be combined only when alternatives are inadequate, at the lowest doses for the shortest time. second, benzodiazepines carry risks of abuse, misuse and addiction that can lead to overdose or death, and prescribers should assess that risk before and during treatment. third, continued use can cause physical dependence, and stopping abruptly or cutting the dose quickly can cause withdrawal reactions that can be life-threatening, so the dose should come down by a gradual taper. it is a warning about how the drug is used, not an instruction to stop it.
- is alprazolam addictive?
- the label says benzodiazepines expose users to risks of abuse, misuse and addiction, that even taking them as prescribed may put people at risk of misuse, and that physical dependence, a separate thing from addiction, can develop with continued use, with "some risk of dependence" even after short-term use below 4 mg a day. the risk and severity rise above 4 mg a day and beyond 12 weeks. dependence means withdrawal symptoms on stopping, which the label says can be life-threatening and can in some people last more than a year. that is why it says to taper rather than stop.
- what are the most common alprazolam side effects?
- in the label’s 4-week anxiety trials at up to 4 mg: drowsiness 41% vs 22% on placebo, light-headedness 21% vs 19%, dry mouth 15% vs 13%. in the panic trials at up to 10 mg: drowsiness 77% vs 43%, fatigue 49% vs 42%, impaired coordination 40% vs 18%, memory impairment 33% vs 22%, slurred speech 23% vs 6%, constipation 26% vs 15%, increased appetite 33% vs 23%, weight gain 27% vs 18%, decreased libido 14% vs 8%. the label says little tolerance develops to the memory and cognitive effects.
- what happens if you stop alprazolam suddenly?
- the label says abrupt stopping or a rapid dose cut after continued use can cause acute withdrawal reactions that can be life-threatening, including seizures. its own taper instruction is to reduce by no more than 0.5 mg every 3 days, slower if needed, pausing or stepping back up if withdrawal appears, and it says some people prove resistant to every schedule. when 641 people in the panic trials came off the drug, the most common symptoms were insomnia (29.5%), light-headedness (19.3%), anxiety (19.2%), fatigue (18.4%), involuntary movements (17.3%) and headache (17.0%). a protracted syndrome can last weeks to more than 12 months. a taper plan belongs with a prescriber.
- can you take alprazolam with opioids or alcohol?
- the boxed warning says benzodiazepines with opioids may cause profound sedation, respiratory depression, coma and death, and that the combination should be reserved for people with no adequate alternative, at the lowest doses for the shortest time, with a lower starting dose of whichever drug is added. the label also says to avoid alcohol and other sedatives. in the studies behind the warning, people filling both prescriptions had about twice the odds of an overdose emergency visit, and a benzodiazepine was present in one in three prescription-opioid overdose deaths in 2017. if either drug is prescribed, the label puts the duty to know about the other on the prescriber; the person who can make sure both prescribers know is the patient.
- does alprazolam cause dementia?
- unsettled, and the two best studies point in opposite directions. a 2014 case-control study of 1,796 older adults with alzheimer’s disease found past benzodiazepine use beyond three months associated with about 1.5 times the odds, rising to 1.8 with longer use. a 2016 prospective cohort of 3,434 adults aged 65 and over, followed for 7.3 years, found no increased dementia risk in the heaviest users (hazard ratio 1.07) and no dose-response, which argues against causation; anxiety and insomnia can be early symptoms of dementia that lead to a prescription years before diagnosis. what is better established is that long-term users score worse on cognitive tests while taking the drug, and the label says tolerance to those effects is limited.
sources for this section
the library rows link to our one-page summary of each study, with the original paper, its funding and our evidence grade on that page.
- alprazolam tablets prescribing information, fda label on dailymed (set id 563e09db-2f3d-4ce8-b356-ae44477be6d0, version 2, effective august 27, 2026): boxed warning; sections 1, 2.1 to 2.6, 4, 5.1 to 5.9, 6.1 tables 1 to 3, 9.1 to 9.3, 14.1, 14.2
- ahrq medical expenditure panel survey, prescribed medicines public-use files 2014 (hc-168a) and 2024 (hc-254a): people with at least one alprazolam purchase, weighted; computed by veisund, method on the usage section of this page
- fda drug safety communication, september 2020: fda requiring boxed warning updated to improve safe use of benzodiazepine drug class (library row)
- benzodiazepines and opioids together: the boxed warning on every benzodiazepine label (xanax xr prescribing information, boxed warning, 5.1 and 7.1, read june 2026) (library row)
- sun ec, et al. association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis. bmj 2017 (library row)
- tori me, larochelle mr, naimi ts. alcohol or benzodiazepine co-involvement with opioid overdose deaths in the united states, 1999 to 2017. jama network open 2020 (library row)
- gladden rm, et al. changes in opioid-involved overdose deaths by opioid type and presence of benzodiazepines, cocaine, and methamphetamine, 25 states, 2017 to 2018. mmwr 2019 (library row)
- national institute for health and care excellence. medicines associated with dependence or withdrawal symptoms (ng215), 2022 (library row)
- baandrup l, et al. pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users. cochrane database of systematic reviews 2018 (library row)
- markowitz js, et al. effect of st john’s wort on drug metabolism by induction of cytochrome p450 3a4 enzyme. jama 2003 (library row)
- ballenger jc, et al. alprazolam in panic disorder and agoraphobia: results from a multicenter trial. i. efficacy in short-term treatment. archives of general psychiatry 1988 (library row)
- guaiana g, et al. pharmacological treatments in panic disorder in adults: a network meta-analysis. cochrane database of systematic reviews 2023 (library row)
- moylan s, et al. the efficacy and safety of alprazolam versus other benzodiazepines in the treatment of panic disorder. journal of clinical psychopharmacology 2011 (library row)
- gray sl, et al. benzodiazepine use and risk of incident dementia or cognitive decline: prospective population based study. bmj 2016 (library row)
- billioti de gage s, et al. benzodiazepine use and risk of alzheimer’s disease: case-control study. bmj 2014 (library row)
- barker mj, et al. cognitive effects of long-term benzodiazepine use: a meta-analysis. cns drugs 2004 (library row)
How long the alprazolam trials actually ran
The longest trial behind the alprazolam approval ran 10 weeks.
The gap between how long the trials ran and how long people actually take these medications is the single most important thing on this page. It is not evidence that longer use is unsafe or ineffective. It is evidence that longer use was not what got tested.
People often stay on these drugs for far longer than the trials ran. The anxiety trials ran 4 weeks. The panic trials ran up to 10 weeks.
That does not mean longer use is unsafe. It does not mean the drug stops working either. It means longer use was never the thing that got tested.
If you have been on it a long time, that is a fair thing to ask your prescriber about.
Boxed warning: risks from use with opioids
The strongest warning the FDA puts on a label, often called a black box warning. It is reproduced below word for word, not summarised.
This is the strongest warning the FDA can put on a drug label. Some people call it a black box warning. We copied it word for word. We did not shorten it and we did not soften it.
The alprazolam boxed warning covers risks from use with opioids; abuse, misuse, and addiction; dependence and withdrawal reactions.
The warning below covers three things. First, taking this drug with an opioid can cause deep sedation, slowed breathing, coma, and death. Second, it can be abused and misused. That can lead to addiction, overdose, and death. Third, taking it day after day can lead to physical dependence. Stopping fast after that can set off withdrawal. The label says that withdrawal can be life threatening, so it says to come off slowly.
The FDA’s own words follow, copied exactly.
WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation [see Warnings and Precautions ( 5.1 ), Drug Interactions ( 7.1 )]. The use of benzodiazepines, including alprazolam tablets, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing alprazolam tablets and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction [see Warnings and Precautions ( 5.2 )]. The continued use of benzodiazepines, including alprazolam tablets, may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Abrupt discontinuation or rapid dosage reduction of alprazolam tablets after continued use may precipitate acute withdrawal reactions, which can be life-threatening. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue alprazolam tablets or reduce the dosage [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.3 )]. WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS See full prescribing information for complete boxed warning. Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation. ( 5.1 , 7.1 ) The use of benzodiazepines, including alprazolam tablets, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Before prescribing alprazolam tablets and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction. ( 5.2 ) Abrupt discontinuation or rapid dosage reduction of alprazolam tablets after continued use may precipitate acute withdrawal reactions, which can be life-threatening. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue alprazolam tablets or reduce the dosage. ( 2.2 , 5.3 )
FDA label effective August 27, 2026 — read the full label on DailyMed
What alprazolam is FDA approved for, and what the record shows
Approved for the acute treatment of generalized anxiety disorder and the treatment of panic disorder, with or without agoraphobia, in adults in 1981, under application NDA 018276. Source: FDA Drugs@FDA.
The label never states how many generalized-anxiety trials were run or reports their individual results, and the FDA's 1981 review of the original application has not been published. What follows is what the label itself states about the trials.
For generalized anxiety disorder, the label describes double-blind, 4-week placebo-controlled studies at doses up to 4 mg per day; it does not say how many there were, and the trial sizes it reports come from the pooled side-effect tables — 565 patients on alprazolam against 505 on placebo. The panic-disorder indication rests on 3 short-term placebo-controlled studies of up to 10 weeks at doses up to 10 mg per day.
Two gaps first. The label never says how many anxiety trials were run. It never gives their separate results either. The FDA has also never published its 1981 review of the first application. So what follows is only what the label itself says.
The FDA approved alprazolam in 1981. There were two approved uses. One is short-term treatment of generalized anxiety disorder in adults. The other is treatment of panic disorder in adults, with or without a fear of public places (agoraphobia). The file number is NDA 018276. The source is Drugs@FDA, the FDA's own database.
For generalized anxiety, the label describes 4-week trials against a placebo. Doses went up to 4 mg a day. Nobody in them knew who got the drug (double-blind). The label does not say how many of these trials there were.
The group sizes it does give come from its pooled side effect tables. Those were 565 people on the drug and 505 on a placebo.
The panic disorder use rests on 3 short trials against a placebo. Those ran up to 10 weeks. Doses went up to 10 mg a day.
- Duration
- 4 weeks (anxiety); up to 10 weeks (panic)
- Participants
- 565 patients on alprazolam vs 505 on placebo (anxiety trials)
- Compared against
- Placebo
Alprazolam was compared to placebo in double-blind clinical studies (doses up to 4 mg per day) in patients with a diagnosis of anxiety or anxiety with associated depressive symptomatology.
Verbatim from the alprazolam FDA label, Clinical Studies section, effective August 27, 2026 — read the full label on DailyMed.
Side effects of alprazolam listed on the FDA label
Incidence among 565 patients on alprazolam versus 505 on placebo in the 4-week placebo-controlled trials for generalized anxiety disorder, the original indication, at doses up to 4 mg per day. The label states that these rates may not reflect the rates observed in practice; the later panic-disorder trials, at higher doses, reported substantially higher rates of sedation-related effects.
Read the limits first. These numbers come from the 4-week anxiety trials. That was the first approved use, at doses up to 4 mg a day. 565 people took the drug and 505 took a placebo.
The label says these rates may not match what happens in real life. The later panic trials used higher doses. In those, sedation effects were reported far more often.
Akathisia on the alprazolam label
The alprazolam FDA label names akathisia in its Adverse Reactions section, in the list below.
- Drowsiness (41% vs 22% on placebo)
- Light-headedness (21% vs 19%)
- Dry mouth (15% vs 13%)
- Hypotension (5% vs 2%)
- Increased salivation (4% vs 2%)
- Dermatitis/allergy (4% vs 3%)
- Dizziness (2% vs 1%)
- Akathisia (2% vs 1%)
The most common adverse reactions reported in clinical trials for generalized anxiety disorder and panic disorder (incidence > 5% and at least twice that of placebo) include: impaired coordination, hypotension, dysarthria, and increased libido.
From the alprazolam FDA label, Adverse Reactions section, effective August 27, 2026 — DailyMed.
More from the alprazolam label: drug abuse and dependence
Schedule IV controlled substance
Alprazolam is a Schedule IV controlled substance under the Controlled Substances Act. The label describes it as a benzodiazepine and CNS depressant with a potential for abuse and addiction, and notes that even taking it as prescribed may put patients at risk for abuse and misuse.
FDA label, Drug Abuse and Dependence section.
Dependence can follow ordinary use
Per the label, even relatively short-term use at doses under 4 mg/day carries some risk of dependence; spontaneous-report data suggest the risk and its severity appear greater above 4 mg/day and beyond 12 weeks. Discontinuation calls for a gradual, patient-specific taper, since abrupt stopping can precipitate withdrawal reactions — including seizures — that can be life-threatening.
FDA label, Warnings and Precautions section.
Anxiety between doses
Early-morning anxiety and the emergence of anxiety symptoms between doses have been reported in panic-disorder patients on prescribed maintenance doses. The label attributes this to developing tolerance or to a dosing interval that outlasts the drug's clinical action.
FDA label, Warnings and Precautions section.
How many Americans take alprazolam
Survey-based federal estimates, published with a lag of about two years. They count prescriptions filled, not outcomes.
These are federal survey numbers. They come out about two years late. They count prescriptions filled. They do not tell you if the drug helped.
- 12,541,990
- prescriptions in the United States (2024), refills included
- 3,426,968
- people filling them (2024), ± 503,279 (95%)
Prescriptions are down 57% from 2014 to 2024, a change larger than the survey’s margin of error. Whatever you decide about alprazolam, you are deciding alongside about 3,426,968 other people in 2024.
Prescriptions by year: 2014 28,897,889 · 2015 27,051,071 · 2016 27,030,725 · 2017 25,516,329 · 2018 20,859,431 · 2019 17,533,262 · 2020 16,780,806 · 2021 15,380,321 · 2022 14,988,527 · 2023 15,881,367 · 2024 12,541,990.
Prescriptions are down 57 percent since 2014. About 3.4 million people in the United States took it in 2024.
Correction (29 September 2026). An earlier version of this section took its numbers from ClinCalc DrugStats, a third-party site that republishes this survey; we now compute them from AHRQ’s public-use files ourselves.
Source: AHRQ Medical Expenditure Panel Survey (MEPS), Prescribed Medicines public-use files, 2014 (HC-168A) through 2024 (HC-254A), computed by veisund. People with at least one purchase where the Multum generic name (RXDRGNAM) equals the drug, weighted by the year’s person weight; purchases include refills. Standard errors by Taylor linearization on VARSTR/VARPSU. AHRQ’s reliability rule: a year is not shown when fewer than 60 survey respondents reported the drug or the relative standard error is over 50%. AHRQ cautions that its 2018 questionnaire redesign and the 2020–2022 pandemic years make year-to-year comparisons less certain.
What people report to the FDA about alprazolam
Read this before the numbers.
Anyone can file an adverse event report — patients, doctors, manufacturers — and nobody verifies that the drug caused what was reported. There is no denominator: tens of millions of prescriptions generate reports at an unknowable rate, and reporting rises with news coverage, not necessarily with harm. Counts below are report volumes, not rates, and cannot be compared between drugs. The FDA itself says not to use this data to make medical decisions — we show it because you deserve to see what is in the public record, with its limits stated plainly.
Read this before the numbers.
Anyone can send a report to the FDA. Patients can. Doctors can. Drug makers can. Nobody checks that the drug caused what the report describes.
There is also no bottom number. Tens of millions of prescriptions turn into reports at a rate nobody knows. Reports go up when a drug is in the news, and that is not the same as more harm.
So these are counts of reports. They are not rates. You cannot use them to compare one drug with another. The FDA itself says not to use this data to make medical choices.
We show it because it is on the public record, and you should get to see it with its limits named.
- 204,912
- reports mentioning alprazolam, all time
- 144,784
- filed as serious (a report-level flag covering every drug and outcome in the report)filed as serious. That flag covers the whole report, and one report can name more than one drug and more than one outcome.
Most-reported reactions
- Drug ineffective13,641
- Nausea13,088
- Fatigue12,190
- Drug abuse11,119
- Anxiety10,314
- Headache10,117
- Pain9,969
- Toxicity to various agents9,058
- Diarrhoea9,013
- Dyspnoea8,435
“Drug ineffective” ranking this high is worth noticing: a report of not being helped counts as an adverse event too, and people file them in large numbers.
It is worth noticing how high “drug ineffective” ranks. A report that the drug did not help counts as an adverse event too. People file a lot of them.
Source: FDA Adverse Event Reporting System (FAERS), via openFDA, openFDA dataset refreshed 2026-07-30 (the refresh date of the query endpoint, not the date reports run through).
Drug interactions listed on the alprazolam label
The FDA label’s interactions section, verbatim. A pharmacist checking your actual medication list beats any published list — including this one.
Below is the part of the FDA label that lists other drugs. It is copied word for word.
No list on the web can see what else you take. A pharmacist can. Ask one to check your full list.
Read the label’s interactions section
7 DRUG INTERACTIONS Use with Opioids: Increase the risk of respiratory depression. ( 7.1 ) Use with Other CNS Depressants: Produces additive CNS depressant effects. ( 7.1 ) Use with Digoxin: Increase the risk of digoxin toxicity. ( 7.1 ) Use with CYP3A Inhibitors (except ritonavir): Increase the risk of adverse reactions of alprazolam. ( 4 , 5.5 , 7.1 ) Use with CYP3A Inducers: Increase the risk of reduced efficacy of alprazolam. ( 7.1 )
7.1 Drugs Having Clinically Important Interactions with Alprazolam Table 4 includes clinically significant drug interactions with alprazolam [see Clinical Pharmacology ( 12.3 )] . Table 4: Clinically Significant Drug Interactions with Alprazolam Opioids Clinical implication The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at gammaaminobutyric acid(GABA A ) sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Prevention or management Limit dosage and duration of concomitant use of alprazolam and opioids, and monitor patients closely for respiratory depression and sedation [see Warnings and Precautions ( 5.1 )]. Examples Morphine, buprenorphine, hydromorphone, oxymorphone, oxycodone, fentanyl, methadone, alfentanil, butorpenol, codeine, dihydrocodeine, meperidine, pentazocine, remifentanil, sufentanil, tapentadol, tramadol. CNS Depressants Clinical implication The benzodiazepines, including alprazolam, produce additive CNS depressant effects when coadministered with other CNS depressants. Prevention or management Limit dosage and duration of alprazolam during concomitant use with CNS depressants [see Warnings and Precautions ( 5.3 )] . Examples Psychotropic medications, anticonvulsants, antihistaminics, ethanol, and other drugs which themselves produce CNS depression. Strong Inhibitors of CYP3A (except ritonavir) Clinical implication Concomitant use of alprazolam with strong CYP3A inhibitors has a profound effect on the clearance of alprazolam, resulting in increased concentrations of alprazolam and increased risk of adverse reactions [see Clinical Pharmacology ( 12.3 )]. Prevention or management Concomitant use of alprazolam with a strong CYP3A4 inhibitor (except ritonavir) is contraindicated [see Contraindications ( 4 ), Warnings and Precautions ( 5.5 )]. Examples Ketoconazole, itraconazole, clarithromycin Moderate or Weak Inhibitors of CYP3A Clinical implication Concomitant use of alprazolam with CYP3A inhibitors may increase the concentrations of alprazolam, resulting in increased risk of adverse reactions of alprazolam [see Clinical Pharmacology ( 12.3 )]. Prevention or management Avoid use and consider appropriate dose reduction when alprazolam is coadministered with a moderate or weak CYP3A inhibitor [see Warnings and Precautions ( 5.5 )]. Examples Nefazodone, fluvoxamine, cimetidine, erythromycin CYP3A Inducers Clinical implication Concomitant use of CYP3A inducers can increase alprazolam metabolism and therefore can decease plasma levels of alprazolam [see Clinical Pharmacology ( 12.3 )] . Prevention or management Caution is recommended during coadministration with alprazolam. Examples Carbamazepine, phenytoin Ritonavir Clinical implication Interactions involving ritonavir and alprazolam are complex and time dependent. Short term administration of ritonavir increased alprazolam exposure due to CYP3A4 inhibition. Following long term treatment of ritonavir (>10 to 14 days), CYP3A4 induction offsets this inhibition. Alprazolam exposure was not meaningfully affected in the presence of ritonavir. Prevention or management Reduce alprazolam dosage when ritonavir and alprazolam are initiated concomitantly, or when ritonavir is added to a regimen where alprazolam is stabilized. Increase alprazolam dosage to the target dosage after 10 to 14 days of dosing ritonavir and alprazolam concomitantly. No dosage adjustment of alprazolam is necessary in patients receiving ritonavir for more than 10 to14 days [see Dosage and Administration ( 2.6 )] . Concomitant use of alprazolam with a strong CYP3A inhibitor, except ritonavir, is contraindicated [see Contraindications ( 4 ), Warnings and Precautions ( 5.5 )]. Digoxin Clinical implication Increased digoxin concentrations have been reported when alprazolam was given, especially in geriatric patients( >65 years of age). Prevention or management In patients on digoxin therapy, measure serum digoxin concentrations before initiating alprazolam. Continue monitoring digoxin serum concentration and toxicity frequently . Reduce the digoxin dose if necessary.
7.2 Drug/Laboratory Test Interactions Although interactions between benzodiazepines and commonly employed clinical laboratory tests have occasionally been reported, there is no consistent pattern for a specific drug or specific test.
FDA label for alprazolam, effective August 27, 2026 — DailyMed.
Label history: when this label changes, it is recorded in What changed.
Who pays for alprazolam
Two claims datasets and one survey, covering different populations with different instruments — they cannot be reconciled by arithmetic, and where their sum crowds the all-payer estimate, that is a finding about the estimates rather than a percentage.
- Medicare Part D
- Read the under-65 group correctly before the numbers: Medicare before 65 means the disabled and dual-eligible population — among the sickest, highest-need people in the program — and reading their utilization as typical adult use would be a category error. The beneficiary total sums brand-level rows, so treat it as an upper bound on distinct people. 2,316,589 beneficiaries filled 11,707,746 claims in 2024 — 1,966,784 aged 65 and over, and 349,805 under 65.
- Medicaid
- At least 3,090,918 prescriptions in 2024 — a floor, because 121 of 724 national data rows are suppressed for privacy and contribute zero. Medicaid covers more children than any insurer in the country and publishes no age split — how much of this number is pediatric use is not knowable from public data.
- All payers (survey estimate)
- A survey estimate from 206 respondents, which we computed from AHRQ’s MEPS 2024 Prescribed Medicines file (people with at least one purchase, weighted; purchases include refills), puts the whole country at 12,541,990 purchases and 3,426,968 people in 2024. Subtracting the public programs from it would produce a number for everyone else — and we do not print that number, because subtracting a survey from claims counts manufactures precision that does not exist.
- The population nobody counts
- The commercially insured working-age adult — statistically, the likeliest person to be reading this page — is the one population with no public per-drug count anywhere. Private claims data exists and is sold, but nothing a patient can check is published. For children the record is thinner still: no public source counts pediatric use of alprazolam specifically; the closest the public record comes is condition-level treatment rates for children, which we have traced for one condition in how childhood ADHD got counted.
Sources: Medicare Part D Prescribers — by Geography and Drug, data.cms.gov, National rows, data year 2024 (published with ~17-month lag). Medicaid State Drug Utilization Data 2024, data.medicaid.gov, national aggregate rows. Retrieved 2026-09-01.
Who has been paying for alprazolam, 2019–2024
Medicare Part D
Claims, all ages — the one payer with a public per-drug series.
12,748,982 → 11,707,746 claims
Medicare under 65
Beneficiaries, not ordinary working-age adults: Medicare before 65 means the disabled and dual-eligible population. A gap is a suppressed split, not zero.
514,868 → 349,805 beneficiaries
Medicaid
A floor each year — small-cell rows are suppressed federally and excluded from the sum.
3,983,001 → 3,090,918 prescriptions (floor)
Commercially insured adults
No public dataset publishes per-drug commercial claims for any year — the absence is the finding, and it is rendered, not interpolated. The population this library most wants to inform is the one with no public per-drug series, in any year — insurers and PBMs hold that data privately. What the federal surveys do measure — how many adults take these medications at all — is on the adult-usage page.
Sources: Medicare Part D Prescribers by Geography and Drug (data.cms.gov, national rows, per data year); Medicaid State Drug Utilization Data (data.medicaid.gov, national rows). Claims, fills and beneficiaries are different units — compare each series only with itself.
The alprazolam approval, step by step
Step 1
What the approval was actually based on
Which studies did the FDA rely on, how long did they run, and who was in them?
Alprazolam was significantly better than placebo at each of the evaluation periods of these 4-week studies... The effectiveness of alprazolam in the treatment of panic disorder was studied in 3 short-term, placebo-controlled studies (up to 10 weeks) in patients with diagnoses closely corresponding to DSM-III-R criteria for panic disorder.
FDA-approved labelling, 14 CLINICAL STUDIES 14.1 Generalized Anxiety Disorder / 14.2 Panic Disorder — read the label on DailyMed
Our reading
Anxiety: four-week studies. Panic: three studies of up to ten weeks. This is the starkest duration gap in the whole directory — a medication whose efficacy was demonstrated over four weeks, which people are commonly prescribed for years, and whose boxed warning about physical dependence was not strengthened until 2020, thirty-nine years after approval.
Step 2
The approval
When was it approved, under what application, and by whose review?
- Approved
- October 16, 1981
- Application
- NDA018276
- Review
- STANDARD
- Original sponsor
- Upjohn
- Holds it now
- Upjohn
- Label submissions since
- 40
Source: openFDA Drugs@FDA, original application ORIG-1
Step 3
What was added after it was on the market
Which warnings arrived only after millions of people were already taking it?
The FDA strengthened the benzodiazepine warning in 2020
39 years after approval
In September 2020 the FDA required the boxed warning on every benzodiazepine to be rewritten. The wording matters: physical dependence can develop even when the medication is taken exactly as prescribed, and stopping abruptly or dropping the dose quickly can cause withdrawal reactions that include seizures and can be life-threatening.
This is not a claim that the medication is bad or that you should stop taking it. It is the opposite. It is the reason not to stop on your own. The FDA's own instruction to prescribers is to taper gradually rather than stop, and to reassess dose and duration over time.
Worth asking
How long is the plan for me to be on this, what does my taper look like if we decide to come off, and how will we tell withdrawal apart from my original anxiety coming back.
Benzodiazepines and opioids together: the boxed warning on every benzodiazepine label
45 years after approval
The strongest warning the FDA can require sits at the top of every benzodiazepine label, and its first bullet is about a combination.
Significant findings
The XANAX XR prescribing information (Viatris, June 2026) opens: "Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation."
The label explains why the two add up rather than cancel: "The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at gamma-aminobutyric acid (GABAA) sites and opioids interact primarily at mu receptors." And it states the evidence base: "Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioids alone."
The same boxed warning names alcohol and other sedatives: "Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes." Alprazolam is also contraindicated with strong CYP3A inhibitors such as ketoconazole and itraconazole, because they raise its blood level, and the dose is halved when ritonavir is started.
Worth asking
If you take a benzodiazepine and are prescribed an opioid for pain, or a cough medicine containing one, the question for whoever prescribes the second drug is whether they know about the first. The label puts the responsibility on the prescriber to limit doses and durations and to watch for slowed breathing; the person who can make sure both prescribers know is you. Do not stop a benzodiazepine on your own: the same label carries a warning about withdrawal, which can be severe, and any change belongs in a conversation with the prescriber.
Step 4
What independent research has found since
What has been learned by people who were not selling it?
Opioid users who also filled a benzodiazepine had about twice the odds of an overdose visit
36 years after approval
The label says the combination is dangerous. This is the study that put a number on it, in the year before the FDA required the boxed warning.
Significant findings
Sun and colleagues (BMJ, 2017) analysed claims for 315,428 privately insured people aged 18 to 64 who filled at least one opioid prescription between 2001 and 2013. Concurrent use meant the two prescriptions overlapped by at least one day. "9% of opioid users also used a benzodiazepine in 2001, increasing to 17% in 2013 (80% relative increase). This increase was driven mainly by increases among intermittent, as opposed to chronic, opioid users."
On the outcome: "Compared with opioid users who did not use benzodiazepines, concurrent use of both drugs was associated with an increased risk of an emergency room visit or inpatient admission for opioid overdose (adjusted odds ratio 2.14, 95% confidence interval 2.05 to 2.24; P<0.001) among all opioid users." The odds ratio was 1.42 for intermittent opioid users and 1.81 for chronic users.
The authors' own conditional: "If this association is causal, elimination of concurrent benzodiazepine/opioid use could reduce the risk of emergency room visits related to opioid use and inpatient admissions for opioid overdose by an estimated 15% (95% confidence interval 14 to 16)."
Worth asking
Two things this study is not. It is not a trial, so it cannot prove the benzodiazepine caused the overdoses; people prescribed both may differ in ways claims data cannot see. And it is not about street drugs; every exposure was a filled prescription from a doctor. That second point is the useful one. Both drugs came through a pharmacy, which means a pharmacist can see both. If you take either, ask the pharmacist to check for the other.
Two thirds of opioid overdose deaths in 25 states also involved cocaine, methamphetamine or a benzodiazepine
38 years after approval
The question "is it okay to mix" has a public health answer in the surveillance data: most opioid deaths are already mixtures.
Significant findings
Gladden and colleagues (MMWR, 2019) describe opioid overdose deaths in 25 states participating in the CDC's State Unintentional Drug Overdose Reporting System, comparing January to June 2018 with the previous half year. The background: "From 2013 to 2017, the number of opioid-involved overdose deaths (opioid deaths) in the United States increased 90%, from 25,052 to 47,600. This increase was primarily driven by substantial increases in deaths involving illicitly manufactured fentanyl (IMF) or fentanyl analogs mixed with heroin, sold as heroin, or pressed into counterfeit prescription pills."
The findings: "overall opioid deaths decreased 4.6%"; decreases were in prescription opioid deaths without illicit opioids; and "IMF deaths, especially those with multiple illicit opioids and common nonopioids, increased. Consequently, IMF was involved in approximately two-thirds of opioid deaths during January-June 2018. Notably, during January-June 2018, 62.6% of all opioid deaths co-occurred with at least one common nonopioid drug."
The nonopioid drugs counted were cocaine, methamphetamine and benzodiazepines, detected in the person who died. The report's conclusion: efforts must "address polysubstance misuse with opioids."
Worth asking
Two things this report establishes. Counterfeit pills, including ones sold as Xanax or oxycodone, may be fentanyl; the report says so in its first paragraph. And the deaths are mostly combinations, not single drugs. If you take a prescribed benzodiazepine or stimulant and also use cocaine or pills from outside a pharmacy, the relevant number is not the interaction between your two drugs but the fentanyl you did not know was there. Fentanyl test strips and naloxone are the practical questions.
Benzodiazepines were present in a third of prescription opioid overdose deaths in 2017; alcohol in one in seven
39 years after approval
The label says benzodiazepines plus opioids kill. This is the count.
Significant findings
Tori, Larochelle and Naimi (JAMA Network Open, 2020) analysed every opioid-involved poisoning death in the CDC's WONDER database from 1999 to 2017: "399 230 poisoning deaths involved opioids, of which 263 601 (66.0%) were male, and 204 560 (51.2%) were aged 35 to 54 years."
Alcohol: "Alcohol co-involvement for all opioid overdose deaths increased nonlinearly from 12.4% in 1999 to 14.7% in 2017. By opioid subtype, deaths involving heroin and synthetic opioids (eg, fentanyl; excluding methadone) had the highest alcohol co-involvement at 15.5% and 14.9%, respectively, in 2017."
Benzodiazepines: "Benzodiazepine co-involvement in all OODs increased nonlinearly from 8.7% in 1999 to 21.0% in 2017. Benzodiazepines were present in 33.1% of prescription OODs and 17.1% of synthetic OODs in 2017."
The state-level pattern: "State-level rates of binge drinking were significantly correlated with alcohol co-involvement in all OODs (r = 0.34; P = .02). State benzodiazepine prescribing rates were significantly correlated with benzodiazepine co-involvement in all OODs (r = 0.57; P < .001)."
Worth asking
Co-involvement means the drug was found at death, not that it caused the death, and death certificates undercount what was not tested for. Even so, one in three prescription opioid deaths with a benzodiazepine present is the number behind the boxed warning. If you take a benzodiazepine and any opioid is in your life, prescribed or not, the question for your prescriber is whether naloxone is in the house and whether the people around you know how to use it.
Two weeks of St John's wort doubled the clearance of alprazolam and halved its half-life in healthy volunteers
22 years after approval
St John's wort is taken for mood without a prescription, which means the prescriber of the other drugs often does not know. This trial measured what it does to a common benzodiazepine.
Significant findings
Markowitz and colleagues (JAMA, 2003) ran an open-label crossover study in 12 healthy volunteers aged 22 to 38. Probe drugs, alprazolam for CYP3A4 and dextromethorphan for CYP2D6, were given before and after 14 days of St John's wort, "one 300-mg tablet 3 times per day."
"A 2-fold decrease in the area under the curve for alprazolam plasma concentration vs time (P<.001) and a 2-fold increase in alprazolam clearance (P<.001) were observed following St John's wort administration. Alprazolam elimination half-life was shortened from a mean (SD) of 12.4 (3.9) hours to 6.0 (2.4) hours (P<.001)." The dextromethorphan ratio did not change significantly (P = .26), so CYP2D6 was not induced.
The conclusion: "A 14-day course of St John's wort administration significantly induced the activity of CYP 3A4 as measured by changes in alprazolam pharmacokinetics. This suggests that long-term administration of St John's wort may result in diminished clinical effectiveness or increased dosage requirements for all CYP 3A4 substrates, which represent at least 50% of all marketed medications."
Worth asking
The direction matters. Grapefruit blocks CYP3A4 and raises drug levels; St John's wort induces it and lowers them. The zolpidem label in this wave lists St John's wort as reducing the sleeping pill's effect, and the same enzyme clears many antipsychotics, some antidepressants, oral contraceptives and HIV and transplant drugs. The other risk with St John's wort is the opposite one, serotonin syndrome when it is combined with an SSRI; every SSRI label read for this wave lists it. If you take it, tell the prescriber and the pharmacist, because it will not be on their list unless you put it there.
Higher benzodiazepine doses went with non-response to ketamine for depression, above 8 mg diazepam-equivalent
39 years after approval
Ketamine, from a clinic or from the street, works on the same brain systems benzodiazepines quiet. This study asked whether the sedative blunts the antidepressant.
Significant findings
Andrashko and colleagues (Frontiers in Psychiatry, 2020) analysed 47 patients with major depression who had not responded to at least one antidepressant and received a single infusion of racemic ketamine, 0.54 mg per kilogram, on top of their existing medication. "Thirteen patients (28%) reached ≥ 50% reduction in MADRS within one week after ketamine administration. Nineteen (40%) patients took concomitant benzodiazepines on a daily basis."
"The doses of BZDs were significantly higher in nonresponders (p=0.007). ROC analysis distinguished responders from nonresponders by a criterion of >8mg of diazepam equivalent dose (DZ equivalent) with a sensitivity of 80% and a specificity of 85% (p<0.001)." Patients above that dose had "a significantly worse outcome" on day 3 and day 7.
"The results of the study indicate that concomitant benzodiazepine treatment in higher doses may attenuate ketamine's antidepressant effect." A 2015 letter by Frye, Blier and Tye in the Journal of Clinical Psychopharmacology, read for this wave, reported the same pattern under the title "Concomitant benzodiazepine use attenuates ketamine response".
Worth asking
Forty seven patients and a retrospective split, so the cut-off is a hypothesis, not a rule. The direction is consistent across the two reports, and it matters in both settings: a person paying for ketamine treatment while on a moderate benzodiazepine dose may be paying for less effect, and a person using street ketamine on top of a benzodiazepine is combining two sedatives, which the esketamine label in this wave addresses directly. If ketamine treatment is on the table, the question for the clinic is what your benzodiazepine dose is in diazepam-equivalents and whether that changes the plan. Any change to the benzodiazepine is the prescriber's, with a taper; the same drugs cause dangerous withdrawal if stopped abruptly.
Withdrawal from these medications can take months, and NICE says so
41 years after approval
NICE guideline NG215 covers safe prescribing and managed withdrawal for five groups of medication: opioids, benzodiazepines, gabapentinoids, Z-drugs and antidepressants. It is the closest thing there is to an official answer on how coming off actually goes.
It states that withdrawal can be difficult and may take several months or more, that symptoms vary widely in type and severity, that they affect both physical and mental health, and that they can be delayed in onset and can persist. Two recommendations are worth quoting to a prescriber. Do not stop a medicine abruptly except in exceptional medical circumstances. And taper using a slow, stepwise reduction proportionate to the current dose, so the decrements get smaller as the dose gets lower — not a fixed cut each time.
That last detail is the one most commonly missed. Gabapentinoids are the exception in the guideline and are reduced by a fixed amount at each step.
Worth asking
Can we write the taper down, what size are the steps near the end, and how long do I hold at each step before the next reduction.
Pharmacological treatments in panic disorder in adults: a network meta-analysis
42 years after approval
Across 70 randomized trials (up to 12,310 people in the largest analysis), alprazolam was among the most effective and best-tolerated drugs for panic disorder, and one of only two that clearly reduced panic-attack frequency versus placebo, though the review judged the underlying trial quality low enough to limit confidence.
Worth asking
Alprazolam performs well for short-term panic relief in trials - how do we balance that against dependence risk if I end up needing treatment for months, not weeks?
Benzodiazepine use and risk of incident dementia or cognitive decline: prospective population based study
35 years after approval
Following 3,434 adults aged 65+ for a mean of 7.3 years, the highest cumulative benzodiazepine users showed no increased dementia risk (hazard ratio 1.07, 95% CI 0.82 to 1.39), a result that argues against a causal benzodiazepine-dementia link.
Worth asking
The dementia evidence on benzodiazepines points both ways - how do you weigh it for someone my age, and does it change how long I should stay on this?
Benzodiazepine use and risk of Alzheimer's disease: case-control study
33 years after approval
Comparing 1,796 older adults with Alzheimer's disease against 7,184 matched controls, past benzodiazepine use beyond 3 months was associated with roughly 1.5-times higher odds of Alzheimer's, rising to 1.8-times with longer cumulative use.
Worth asking
Given the debated association between long-term benzodiazepine use and dementia, does my expected duration on alprazolam keep me clearly in short-term territory?
The efficacy and safety of alprazolam versus other benzodiazepines in the treatment of panic disorder
30 years after approval
Pooling 8 randomized trials (at least 631 patients), alprazolam was no more effective than other benzodiazepines for panic disorder on panic-attack frequency, anxiety scores, or the share of patients who became panic-free.
Worth asking
Since alprazolam isn't more effective than longer-acting benzodiazepines, would a longer-acting option with a smoother wear-off be a better fit for me?
Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment
7 years after approval
In an 8-week placebo-controlled trial of 526 people with panic disorder or agoraphobia with panic attacks, 50% on alprazolam were free of panic attacks at week 4 versus 28% on placebo, with benefit appearing in the first week.
Worth asking
Alprazolam works fast for panic - what's our plan for how long I stay on it, and how would we eventually taper off?
Step 5
What still is not known
Which questions you might reasonably have has nobody answered yet?
- The trials ran four to ten weeks. Physical dependence develops within weeks of daily use. The approval period barely overlapped the window in which dependence begins.
- There is no registration-era evidence about taking it for years, because nobody was asked to produce any.
- What does a taper look like, and who supervises it? The label says do not stop abruptly; it does not say how to stop.
Deciding about alprazolam?
- Side-effect rates from alprazolam's own label — drug vs placebo, with every caveat the label attaches
- How long every medication's approval trials ran — alprazolam beside every other drug in the library, from the same FDA record
- 12 questions to ask before starting a psychiatric medication — each with the study behind it
- Already on it? The 10-question annual review — including the honest case for staying
- How long every drug here was tested before approval — one chart, all medications
Open alprazolam (Xanax) in veisund
The app has the full approval journey, the resources behind it, and people working through the same questions.
